Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis

The Lancet Psychiatry

Volumn 3, Issue 3, 2016, Pages 215-225

  Schoeler, Tabea ^a   Monk, Anna ^a   Sami, Musa B ^a   Klamerus, Ewa ^a   Foglia, Enrico ^a   Brown, Ruth ^a   Camuri, Giulia ^a   Altamura, A Carlo ^b   Murray, Robin ^a   Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADVERSE OUTCOME; ARTICLE; CANNABIS USE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; META ANALYSIS; POSITIVE SYNDROME; PSYCHOSIS; RELAPSE; SYSTEMATIC REVIEW; CANNABIS SMOKING; PSYCHOLOGY; PSYCHOTIC DISORDERS; RECURRENT DISEASE;

HUMANS; MARIJUANA SMOKING; PSYCHOTIC DISORDERS; RECURRENCE;

EID: 84959576716     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00363-6     Document Type: Article

References (90)

1. Barrowclough C, Emsley R, Eisner E, Beardmore R, Wykes T Does change in cannabis use in established psychosis affect clinical outcome?. Schizophr Bull 2013, 39:339-348.
2. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010, 36:1115-1130.
3. Addington J, Addington D Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007, 115:304-309.
4. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
5. Agosti V, Nunes E, Levin F Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002, 28:643-652.
6. Arseneault L, Cannon M, Witton J, Murray RM Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004, 184:110-117.
7. Stepniak B, Papiol S, Hammer C, et al. Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. Lancet Psychiatry 2014, 1:444-453.
8. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015, 2:233-238.
9. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008, 193:357-363.
10. van Dijk D, Koeter MWJ, Hijman R, Kahn RS, van Den Brink W Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res 2012, 137:50-57.
11. San L, Bernardo M, Gómez A, Peña M Factors associated with relapse in patients with schizophrenia. Int J Psychiatry Clin Pract 2013, 17:2-9.
12. Sorbara F, Liraud F, Assens F, Abalan F, Verdoux H Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur Psychiatry 2003, 18:133-136.
13. Hides L, Dawe S, Kavanagh D, Young RM Psychotic symptom and cannabis relapse in recent-onset psychosis Prospective study. Br J Psychiatry 2006, 189:137-143.
14. Foti DJ, Kotov R, Guey LT, Bromet EJ Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010, 167:987-993.
15. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005, 20:349-353.
16. Linszen DH, Dingemans PM, Lenior ME Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994, 51:273-279.
17. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005, 57:594-608.
18. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009, 66:442-451.
19. Cortes-Briones JA, Cahill JD, Skosnik PD, et al. The psychosis-like effects of δ-9-THC are associated with increased cortical 'noise' in healthy humans. Biol Psychiatry 2015, 78:805-813.
20. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012, 17:1152-1155.
21. González-Pinto A, Alberich S, Barbeito S, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2009, 37:631-639.
22. van der Meer F, Velthorst E Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol Med 2015, 45:1977-1988.
23. Stone JM, Fisher HL, Major B, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med 2014, 44:499-506.
24. Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert M Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry 2012, 27:463-469.
25. Clausen L, Hjorthøj CR, Thorup A, et al. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med 2013, 44:117-126.
26. Baeza I, Graell M, Moreno D, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res 2009, 113:129-137.
27. Barrowclough C, Gregg L, Lobban F, Bucci S, Emsley R The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophr Bull 2015, 41:382-390.
28. Faber G, Smid HG, Van Gool AR, Wunderink L, van den Bosch RJ, Wiersma D Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial. J Clin Psychiatry 2012, 73:632-638.
29. Harrison I, Joyce EM, Mutsatsa SH, et al. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med 2008, 38:79-88.
30. Kambeitz JP, Bhattacharyya S, Kambeitz-Ilankovic LM, Valli I, Collier DA, McGuire P Effect of BDNF val(66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev 2012, 36:2165-2177.
31. Knapp M, Andrew A, McDaid D, et al. Investing in recovery: making the business case for effective interventions for people with schizophrenia and psychosis 2014, The London School of Economics and Political Science, and Centre for Mental Health, London.
32. Large M, Mullin K, Gupta P, Harris A, Nielssen O Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Aust N Z J Psychiatry 2014, 48:418-432.
33. Gupta P, Mullin K, Nielssen O, Harris A, Large M Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. Aust N Z J Psychiatry 2013, 47:524-537.
34. Mullin K, Gupta P, Compton MT, Nielssen O, Harris A, Large M Does giving up substance use work for patients with psychosis? A systematic meta-analysis. Aust N Z J Psychiatry 2012, 46:826-839.
35. Higgins JP, Green S, Collaboration C Cochrane handbook for systematic reviews of interventions 2008, Wiley, Hoboken, NJ, USA, (accessed Nov 8, 2015). http://handbook.cochrane.org/.
36. Beller EM, Glasziou PP, Altman DG, et al. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med 2013, 10:e1001419.
37. Ringen P, Vaskinn A, Sundet K, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med 2010, 40:1337-1347.
38. Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis. Br J Psychiatry 2014, 204:448-453.
39. Batalla A, Garcia-Rizo C, Castellví P, et al. Screening for substance use disorders in first-episode psychosis: Implications for readmission. Schizophr Res 2013, 146:125-131.
40. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med 2014, 44:2513-2521.
41. Basu D, Malhotra A, Bhagat A, Varma VK Cannabis psychosis and acute schizophrenia. a case-control study from India. Eur Addict Res 1999, 5:71-73.
42. Kazadi N, Moosa M, Jeenah F Factors associated with relapse in schizophrenia. SAJP 2008, 14:52-62.
43. Dervaux A, Laqueille X, Bourdel M, et al. [Cannabis and schizophrenia: demographic and clinical correlates]. Encephale 2002, 29:11-17.
44. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia. Schizophr Bull 1990, 16:31-56.
45. Alterman AI, Erdlen DL, LaPorte DJ, Erdlen FR Effects of illicit drug use in an inpatient psychiatric population. Addict Behav 1982, 7:231-242.
46. Koenders L, Machielsen M, van der Meer F, et al. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci 2014, 40:197-206.
47. Faridi K, Joober R, Malla A Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophr Res 2012, 141:78-82.
48. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R 1987, American Psychiatric Association, American Psychiatric Association, Arlington, VA, USA.
49. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies. Gaceta Sanitaria 2008, 22:144-150.
50. Viechtbauer W Conducting meta-analyses in R with the metafor package. J Stat Soft 2010, 36:1-48.
51. Lane SD, Cherek DR, Lieving LM, Tcheremissine OV Marijuana effects on human forgetting functions. J Exp Anal Behav 2005, 83:67-83.
52. Borenstein M, Hedges LV, Higgins JP, Rothstein HR Introduction to meta-analysis 2011, Wiley, Hoboken, NJ, USA.
53. Cohen J Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ, USA.
54. Del Re AC Package "compute.es" (accessed Nov 8, 2015). https://cran.r-project.org/web/packages/compute.es/compute.es.pdf.
55. Negrete JC, Knapp WP, Douglas DE, Smith WB Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 1986, 16:515-520.
56. Isaac M, Holloway F Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 2005, 20:207-210.
57. Fulham WR, Michie PT, Ward PB, et al. Mismatch negativity in recent-onset and chronic schizophrenia: a current source density analysis. PLoS One 2014, 9:e100221.
58. Egger M, Smith GD, Schneider M, Minder C Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
59. Higgins JPT, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ 2003, 327:557.
60. Addington DE, Patten SB, McKenzie E, Addington J Relationship between relapse and hospitalization in first-episode psychosis. Psychiatr Serv 2013, 64:796-799.
61. Bersani G, Orlandi V, Kotzalidis G, Pancheri P Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002, 252:86-92.
62. Caspari D Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999, 249:45-49.
63. Isaac M, Isaac M, Holloway F Is cannabis an antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 2005, 20:207-210.
64. Jockers-Scherubl MC, Wolf T, Radzei N, et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1054-1063.
65. Linszen DH, Dingemans PM, Lenior ME Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994, 51:273-279.
66. Maremmani I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. J Psychoactive Drugs 2004, 36:235-241.
67. Martinez-Arevalo M, Calcedo-Ordo A, Varo-Prieto J Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994, 164:679-681.
68. Peralta V, Cuesta MJ Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992, 85:127-130.
69. Rehman IU, Farooq S Schizophrenia and comorbid self reported cannabis abuse: impact on course, functioning and services use. J Pak Med Assoc 2007, 57:60.
70. Rentzsch J, Buntebart E, Stadelmeier A, Gallinat J, Jockers-Scherübl MC Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr Res 2011, 130:222-227.
71. Salyers MP, Mueser KT Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 2001, 48:109-123.
72. Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry 2014, 48:1036-1047.
73. van Dijk D, Koeter MW, Hijman R, Kahn RS, van Den Brink W Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res 2012, 137:50-57.
74. Wade D, Harrigan S, Edwards J, Burgess P, Whelan G, McGorry P Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006, 189:229-234.
75. Andreasen NC, Flaum M, Arndt S The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992, 49:615-623.
76. Overall JE, Gorham DR The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
77. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007, 26:4544-4562.
78. Terrin N, Schmid CH, Lau J, Olkin I Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003, 22:2113-2126.
79. Rabin RA, Zakzanis KK, Daskalakis ZJ, George TP Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res 2013, 206:158-165.
80. Kuepper R, van Os J, Lieb R, Wittchen H-U, Höfler M, Henquet C Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011, 342.
81. Degenhardt L, Tennant C, Gilmour S, et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 2007, 37:927-934.
82. Yücel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012, 38:316-330.
83. Ferraro L, Russo M, O'Connor J, et al. Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res 2013, 150:129-135.
84. Bhattacharyya S, Falkenberg I, Martin-Santos R, et al. Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacol 2014, 6:1343-1352.
85. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. Eur Neuropsychopharmacol 2015, 25:26-37.
86. Bhattacharyya S, Crippa J, Allen P, et al. Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012, 69:27-36.
87. Butzlaff RL, Hooley JM Expressed emotion and psychiatric relapse: a meta-analysis. Arch Gen Psychiatry 1998, 55:547-552.
88. Lincoln T, Wilhelm K, Nestoriuc Y Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007, 96:232-245.
89. Leucht S, Arbter D, Engel R, Kissling W, Davis J How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009, 14:429-447.
90. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol 2010, 35:764-774.